BSESupha Pharmachem LtdMediumNeutral
Announced Fri, 31 Oct · 21:58 IST

Appointment

Director Flagged GovernanceKmp ResignedCeo Appointed ExternalManagement Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board, at its October 31, 2025 meeting, appointed two new directors: Mr. Rambhajan Vishwakarma as Non-Executive, Non-Independent Chairman and Mr. Vignesh Laxman Gawde as Whole Time Director for 5 years at a monthly remuneration of Rs. 50,000. The company also approved a postal ballot process that includes a proposed name change (to Remedium Lifecare Limited, as reflected in the signing block), regularization of these appointments, and approval of the WTD's remuneration. All board committees — Audit, NRC, Stakeholders' Relationship, and Risk Management — have been reconstituted with the new directors. Notably, appointments were made without NRC recommendation because the committee was dissolved earlier due to resignations of its director-members.

Likely market impact

Shareholders should note the governance irregularity: the NRC was non-functional due to prior resignations, yet new executive and chairman-level appointments were pushed through. The proposed name change signals a likely business pivot. Investors should watch the postal ballot outcome (deadline December 7, 2025) and any further disclosures about why previous directors resigned.